financetom
Business
financetom
/
Business
/
Nvidia's Data Center Business Seen Driving Second-Quarter Upside, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia's Data Center Business Seen Driving Second-Quarter Upside, UBS Says
Aug 12, 2024 12:10 PM

02:58 PM EDT, 08/12/2024 (MT Newswires) -- Nvidia ( NVDA ) is on track to report stronger-than-expected fiscal second-quarter results later this month amid strength in its data center business, UBS said in a note emailed Monday.

The brokerage forecasts data center revenue as high as $26.3 billion for the July quarter, well above the consensus view of $25 billion. That would mark a quarter-over-quarter improvement of 17%. Shares of Nvidia ( NVDA ) were up 4.7% in afternoon trade.

The indicators UBS relied on for the data center business "skewed bullish," analyst Timothy Arcuri said. Super Micro Computer (SMCI) posted strong results on the back of demand for Nvidia's ( NVDA ) Hopper graphics processing unit while Taiwan Semiconductor (TSM) reported robust quarter-to-quarter growth in high-performance computing, Arcuri wrote.

Other data points include gains in King Yuan Electronics' data processing segment, and robust artificial intelligence server results from Quanta, the UBS report showed.

While Taiwan data processing export numbers point to second-quarter data center revenue below $25 billion, UBS said this indicator has often had high variability in regards to Nvidia's ( NVDA ) results. The Taiwan data also does not include the ramping of Nvidia's ( NVDA ) H20 chips in China and misses other large pieces of Nvidia ( NVDA ) revenue, such as networking, Arcuri said.

UBS is modeling for overall Nvidia ( NVDA ) revenue of $29.93 billion and adjusted earnings per share of $0.68, both above the Wall Street views of $28.6 billion and $0.64, respectively. Nvidia ( NVDA ) is scheduled to report earnings for the period on Aug. 28.

Gaming revenue is forecast to rise 3% quarter over quarter to $2.7 billion, in line with the Street's view but well below the five-year seasonal median of 11% sequential growth, according to Arcuri.

A question mark remaining over guidance is the upcoming launch of Nvidia's ( NVDA ) generative AI GPU platform Blackwell. Management told analysts on the company's first-quarter earnings call that Blackwell would contribute significantly to revenue in 2024, according to the UBS report. However, shipments likely won't begin until the middle of December, Arcuri said.

Price: 109.64, Change: +4.89, Percent Change: +4.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Structure Therapeutics Q3 loss widens to $65.7 mln
Structure Therapeutics Q3 loss widens to $65.7 mln
Nov 6, 2025
Overview * Structure Therapeutics ( GPCR ) reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024 * Company maintains strong cash position of $799 mln, funding operations through 2027 * Phase 1 study for oral amylin receptor agonist ACCG-2671 to start by year-end 2025 Outlook * Structure Therapeutics ( GPCR ) expects topline data from ACCESS...
Trump administration announces Boeing deals in Central Asia
Trump administration announces Boeing deals in Central Asia
Nov 6, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump's administration announced Thursday new deals to sell up to 37 Boeing ( BA ) airplanes to airlines in the Central Asian nations of Kazakhstan, Tajikistan and Uzbekistan. The Commerce Department said Kazakhstan flag carrier Air Astana plans to buy up to 15 Boeing 787-9 Dreamliners to grow and modernize its fleet. The orders were...
BioLife Q3 revenue up 31%, raises 2025 guidance
BioLife Q3 revenue up 31%, raises 2025 guidance
Nov 6, 2025
Overview * BioLife Q3 2025 total revenue rises 31% yr/yr, driven by cell processing growth * Cell processing revenue increases 33% yr/yr * Company raises full-year 2025 revenue guidance to $95.0 mln - $96.0 mln Outlook * BioLife raises 2025 Cell Processing revenue guidance to $93 mln - $94 mln * Company updates 2025 total revenue guidance to $95 mln...
Denali Therapeutics Q3 net loss widens to $126.9 mln
Denali Therapeutics Q3 net loss widens to $126.9 mln
Nov 6, 2025
Overview * Denali Q3 net loss widens to $126.9 mln from $107.2 mln last year * Operating expenses increased due to R&D and commercial launch preparations * FDA extends tividenofusp alfa review timeline to April 2026 from January Outlook * Denali expects to launch tividenofusp alfa for Hunter syndrome after FDA review by April 2026 * Company plans global Phase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved